RLMD News and Press, Relmada Therapeutics Inc. From 08/09/22

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder PR Newswire CORAL GABLES, Fla. , Aug. 9, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stag...

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 PR Newswire CORAL GABLES, Fla. , Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotech...

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial PR Newswire Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Ex...

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 7, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseas...

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 2, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of ...

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, among others. Accordin...

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting PR Newswire CORAL GABLES, Fla. , May 25, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing ...

Relmada Therapeutics, Inc. (RLMD) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors, Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jef...

Relmada Therapeutics press release (NASDAQ:RLMD): Q1 GAAP EPS of -$1.40 misses by $0.13. As of Mar. 31, 2022, the company had cash, cash equivalents, and short-term investments of $220.6M, compared to cash, cash equivalents, and short-term investments of ~$211.9M at December 31, 2021. "We int...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results PR Newswire CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases ...